Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Aug
24
Today In Oncology
Outreach to HCT Recipients, Primary Care Doctors May Reduce Skin Cancer Risk
FDA Seeks Public Input Relating to Regulatory Considerations for Generative AI–Enabled Medical Devices
Pilots and Flight Attendants Show Elevated Radiation-Related Cancer Mortality
INTerpath-001 Trial of mRNA-Based Individualized Neoantigen Therapy Meets Primary and Key Secondary Endpoints in Patients With High-Risk Resected Melanoma
Early Histotripsy Use for Liver Tumors Raises Questions About Patient Selection
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo